Park Chi Young
Department of Internal Medicine, College of Medicine Chosun University, Gwangju, Korea.
Anticancer Drugs. 2009 Oct;20(9):848-9. doi: 10.1097/CAD.0b013e32832fffc7.
Sunitinib is a tyrosine kinase inhibitor with a low toxicity profile and proven activity against metastatic renal cell carcinoma (mRCC). However, there is very limited data on the effect of sunitinib on end stage renal disease owing to mRCC. We report our experience with the use of sunitinib in a patient with mRCC and end stage renal disease undergoing hemodialysis.
舒尼替尼是一种酪氨酸激酶抑制剂，毒性较低，已证实对转移性肾细胞癌（mRCC）有活性。然而，关于舒尼替尼对mRCC所致终末期肾病影响的数据非常有限。我们报告了一名接受血液透析的mRCC和终末期肾病患者使用舒尼替尼的经验。
